Biomarkers of bone metabolism (osteocalcin, β-cross laps, parathormone, serum phosphate, and vitamin D) did not differ significantly between MPN patients with and without sOA (p > 0.05 for all analyses). The gene discussed is BGLAP; the disease is myeloproliferative disorder.